NCT02446223View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Actinic Keratosis
Interventions
DRUG

Inggenol Mebutate 0.015%

Trial Locations (1)

92121

Cosmetic Laser Dermatology, San Diego

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Goldman, Butterwick, Fitzpatrick and Groff

OTHER